LIPO Stock Overview
A biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Lipella Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.63 |
| 52 Week High | US$12.00 |
| 52 Week Low | US$2.21 |
| Beta | 0 |
| 11 Month Change | -26.47% |
| 3 Month Change | -36.72% |
| 1 Year Change | -69.28% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIPO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.4% | 2.4% | 2.2% |
| 1Y | -69.3% | 16.2% | 31.7% |
Return vs Industry: LIPO underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: LIPO underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| LIPO volatility | |
|---|---|
| LIPO Average Weekly Movement | 18.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LIPO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LIPO's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 6 | Jon Kaufman | www.lipella.com |
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc. Fundamentals Summary
| LIPO fundamental statistics | |
|---|---|
| Market cap | US$2.93m |
| Earnings (TTM) | -US$4.26m |
| Revenue (TTM) | US$483.53k |
6.6x
P/S Ratio-0.7x
P/E RatioIs LIPO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPO income statement (TTM) | |
|---|---|
| Revenue | US$483.53k |
| Cost of Revenue | US$3.04m |
| Gross Profit | -US$2.56m |
| Other Expenses | US$1.71m |
| Earnings | -US$4.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.53 |
| Gross Margin | -528.47% |
| Net Profit Margin | -881.73% |
| Debt/Equity Ratio | 0% |
How did LIPO perform over the long term?
See historical performance and comparison